<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079079</url>
  </required_header>
  <id_info>
    <org_study_id>HN4</org_study_id>
    <secondary_id>CAN-NCIC-HN4</secondary_id>
    <secondary_id>LILLY-CAN-NCIC-HN4</secondary_id>
    <secondary_id>CDR0000353487</secondary_id>
    <nct_id>NCT00079079</nct_id>
  </id_info>
  <brief_title>Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor</brief_title>
  <official_title>A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin, carboplatin, and gemcitabine, work&#xD;
      in different ways to stop tumor cells from dividing so they stop growing or die. Giving more&#xD;
      than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemcitabine together with either&#xD;
      cisplatin or carboplatin works in treating patients with locally advanced, recurrent, or&#xD;
      metastatic malignant salivary gland tumor (cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the activity of cisplatin or carboplatin in combination with gemcitabine, in&#xD;
           terms of response rate, in patients with locally advanced, recurrent, or metastatic&#xD;
           malignant salivary gland tumor.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the complete response in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the toxicity profile of these regimens in these patients.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Patients also receive either&#xD;
      cisplatin IV over 1 hour on day 2 OR carboplatin IV over 30 minutes on day 1. Treatment&#xD;
      repeats every 21 days for up to 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks, every 3 months for 1 year, and then every 6 months&#xD;
      thereafter until relapse.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 11- 34 patients will be accrued for this study within 1.5-3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2003</start_date>
  <completion_date type="Actual">February 10, 2009</completion_date>
  <primary_completion_date type="Actual">September 29, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response measured by RECIST criteria after accrual of 11 evaluable patients</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity assessed by NCI CTC v2.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant salivary gland tumor&#xD;
&#xD;
               -  All histological subtypes eligible&#xD;
&#xD;
               -  Locally advanced, recurrent, or metastatic disease&#xD;
&#xD;
               -  Considered incurable by radiotherapy or surgery&#xD;
&#xD;
               -  Low- to intermediate-grade mucoepidermoid tumor or acinic cell carcinoma allowed&#xD;
                  provided patients are symptomatic OR at imminent risk of developing symptoms&#xD;
                  attributable to metastatic disease&#xD;
&#xD;
          -  Disease must meet 1 of the following criteria:&#xD;
&#xD;
               -  Metastatic disease that is chemonaïve&#xD;
&#xD;
               -  Metastatic disease that has progressed after a prior&#xD;
                  non-cisplatin/carboplatin/gemcitabine regimen&#xD;
&#xD;
               -  Local and/or distant recurrence after curative surgery and/or radiotherapy&#xD;
&#xD;
               -  Locally advanced disease not suitable for surgery or radiotherapy&#xD;
&#xD;
          -  At least 1 site of unidimensionally measurable disease documented by 1 of the&#xD;
             following:&#xD;
&#xD;
               -  At least 20 mm by X-ray, physical exam, or non-spiral CT scan&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No bone metastases as only site of measurable disease&#xD;
&#xD;
          -  No known brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST/ALT no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min (for cisplatin) OR 30-59 mL/min (for&#xD;
             carboplatin)&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other serious illness or medical condition that would preclude study participation&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No neurologic disorder or psychiatric illness that would preclude study compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated non-melanoma&#xD;
             skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy for locally advanced, recurrent, or&#xD;
             metastatic disease and recovered&#xD;
&#xD;
               -  Must have been a non-cisplatin/carboplatin/gemcitabine-containing regimen&#xD;
&#xD;
          -  More than 12 months since prior adjuvant chemotherapy (including&#xD;
             cisplatin/carboplatin-based regimens) and recovered&#xD;
&#xD;
          -  No prior gemcitabine&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to only site of measurable disease unless there is documented&#xD;
             disease progression after therapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 21 days since prior surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior anticancer therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian L. Siu, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Laurie SA, Siu LL, Winquist E, Maksymiuk A, Harnett EL, Walsh W, Tu D, Parulekar WR. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer. 2010 Jan 15;116(2):362-8. doi: 10.1002/cncr.24745.</citation>
    <PMID>19924794</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2004</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>salivary gland acinic cell tumor</keyword>
  <keyword>salivary gland adenoid cystic carcinoma</keyword>
  <keyword>salivary gland poorly differentiated carcinoma</keyword>
  <keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
  <keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
  <keyword>salivary gland malignant mixed cell type tumor</keyword>
  <keyword>salivary gland adenocarcinoma</keyword>
  <keyword>salivary gland anaplastic carcinoma</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

